Ipamorelin vs Sermorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicIpamorelinSermorelin
What it is

A synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.5

Growth hormone-releasing factor (human) fragment 1 to 29, amidated, also recorded as groliberin, according to FDA’s substance registry.6

FDA status

Not FDA-approved

Unapproved new drug in cited enforcement record1

Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.4,5

Is ipamorelin FDA-approved?

Not FDA-approved

FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness2,3

Not FDA-approved. FDA withdrew the approvals of both Geref applications, NDA 019863 and NDA 020443, effective June 18, 2009, after the maker discontinued them, according to a 2013 Federal Register notice.2,3

Is sermorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.7

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.7,8

Not among the six peptides the policy lists.7

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Sermorelin is not among them.7,8

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.4

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list sermorelin, either in category 2 or among withdrawn nominations.4

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults after bowel resection, of whom 114 received study drug, published in 2014. FDA reports that its main result was not statistically significant.5
  • Controlled human trial A randomized, placebo-controlled pharmacology study in 48 healthy men that measured blood levels and growth hormone responses. FDA notes it reported no effectiveness data.5

Limited human data

  • Small, short, or incompletely reported human study An open-label, multicenter study in 110 previously untreated children with growth hormone deficiency, without a comparison group, reported by the Geref International Study Group (1996).9
Records collected

2 ClinicalTrials.gov records and 14 PubMed records collected

0 ClinicalTrials.gov records and 2 PubMed records collected

Area of study

Hormones, Gut and digestion5

Hormones2

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.4
  2. FDA’s Pharmacy Compounding Advisory Committee meets to discuss ipamorelin-related substances.5,10
  3. A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss ipamorelin.10
  1. FDA publishes its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness.2
  2. FDA’s withdrawal of both Geref approvals takes effect, at the maker’s request, according to FDA’s 2013 notice.2
  3. FDA approves Geref for growth hormone deficiency in children, NDA 020443.2,3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  2. 2
    Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗

    Federal Register · Official source · Source checked November 15, 2026

  3. 3
    Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  6. 6
    Sermorelin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group (1996) · PMID 8772599 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026

  10. 10
    Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026